<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332616</url>
  </required_header>
  <id_info>
    <org_study_id>HK_VL_08_2014b</org_study_id>
    <nct_id>NCT02332616</nct_id>
  </id_info>
  <brief_title>Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty</brief_title>
  <official_title>Effect of Preoperative Intravenous High Dose Methylprednisolone on Complement Activation in Patients Scheduled for Total Knee-arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the pathophysiological effects of a single dose of methylprednisolone
      administered prior to total knee-arthroplasty surgery. The investigators examine the effect
      on complement activation.

      Half of participants will receive intravenous Solu-Medrol 125 mg, while the other half will
      receive placebo.

      The investigators hypothesize that the group receiving methylprednisolone will experience
      beneficial inhibition of the undesirable parts of the complement activation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The anti-inflammatory effects of glucocorticoids are well known. The beneficial effects on
      postoperative pain, postoperative nausea and vomiting are well-documented.

      Anaesthesia and surgery are associated with a dramatic increase in the inflammatory response.
      The complement system participates in the disposal of products due to inflammatory damage.
      The complement activation generates proinflammatory mediators which amplifies the tissue
      damage and the inflammation.

      Glucocorticoid administration prior to surgery is thought to effectively reduce the
      inflammatory response and the activation of the complement system. The effect of
      glucocorticoids on specific complement markers after surgery is unknown and calls for further
      investigation.

      This study is embedded in a primary study registrated as: NCT02319343

      For further details please view the EudraCT registration:

      EudraCT nr.: 2014-003395-23
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma and serum Pentraxin-3 concentrations from baseline (before surgery) to 48 hours after surgery</measure>
    <time_frame>baseline to 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma and serum Complement Component 3 concentrations from baseline (before surgery) to 48 hours after surgery</measure>
    <time_frame>baseline to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma and serum Complement Component 4 concentrations from baseline (before surgery) to 48 hours after surgery</measure>
    <time_frame>baseline to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma and serum Mannose-binding lectin concentrations from baseline (before surgery) to 48 hours after surgery</measure>
    <time_frame>baseline to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma and serum Ficolin-1, -2 and -3 concentrations from baseline (before surgery) to 48 hours after surgery</measure>
    <time_frame>baseline to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma and serum Terminal Complement Complex concentrations from baseline (before surgery) to 48 hours after surgery</measure>
    <time_frame>baseline to 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Osteoarthrosis</condition>
  <arm_group>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative single high dose of Solu-Medrol 125 mg iv.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotonic Sodium Chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative single dose of isotonic Sodium Chloride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride</description>
    <arm_group_label>Methylprednisolone</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic Sodium Chloride</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Isotonic Sodium Chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthrosis

          -  Undergoing total unilateral knee-arthroplasty surgery

          -  Speak and understand Danish

          -  Have given informed consent

        Exclusion Criteria:

          -  Revision, bilateral or uni chamber knee-arthroplasty surgery

          -  General anaesthesia

          -  Allergy or intolerance towards Methylprednisolone

          -  Local or systemic infection

          -  Permanent systemic treatment with steroids within 30 days preoperatively

          -  Insulin-dependent diabetes

          -  Active treatment of ulcer within 3 months preoperatively

          -  Cancer disease

          -  Autoimmune disease incl. rheumatoid arthritis

          -  Pregnant or breast feeding women

          -  Menopause &lt;1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktoria Lindberg-Larsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Surgical Pathophysiology, Rigshospitalet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Husted H. Fast-track hip and knee arthroplasty: clinical and organizational aspects. Acta Orthop Suppl. 2012 Oct;83(346):1-39. doi: 10.3109/17453674.2012.700593. Review.</citation>
    <PMID>23205862</PMID>
  </reference>
  <reference>
    <citation>Kehlet H. Fast-track hip and knee arthroplasty. Lancet. 2013 May 11;381(9878):1600-2. doi: 10.1016/S0140-6736(13)61003-X.</citation>
    <PMID>23663938</PMID>
  </reference>
  <reference>
    <citation>Khan SK, Malviya A, Muller SD, Carluke I, Partington PF, Emmerson KP, Reed MR. Reduced short-term complications and mortality following Enhanced Recovery primary hip and knee arthroplasty: results from 6,000 consecutive procedures. Acta Orthop. 2014 Feb;85(1):26-31. doi: 10.3109/17453674.2013.874925. Epub 2013 Dec 20.</citation>
    <PMID>24359028</PMID>
  </reference>
  <reference>
    <citation>Malviya A, Martin K, Harper I, Muller SD, Emmerson KP, Partington PF, Reed MR. Enhanced recovery program for hip and knee replacement reduces death rate. Acta Orthop. 2011 Oct;82(5):577-81. doi: 10.3109/17453674.2011.618911. Epub 2011 Sep 6.</citation>
    <PMID>21895500</PMID>
  </reference>
  <reference>
    <citation>Abdelmalak BB, Bonilla AM, Yang D, Chowdary HT, Gottlieb A, Lyden SP, Sessler DI. The hyperglycemic response to major noncardiac surgery and the added effect of steroid administration in patients with and without diabetes. Anesth Analg. 2013 May;116(5):1116-22. doi: 10.1213/ANE.0b013e318288416d. Epub 2013 Apr 4.</citation>
    <PMID>23558840</PMID>
  </reference>
  <reference>
    <citation>Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear T, Vender JS, Gray J, Landry E. The effect of single low-dose dexamethasone on blood glucose concentrations in the perioperative period: a randomized, placebo-controlled investigation in gynecologic surgical patients. Anesth Analg. 2014 Jun;118(6):1204-12. doi: 10.1213/ANE.0b013e3182a53981.</citation>
    <PMID>24299928</PMID>
  </reference>
  <reference>
    <citation>de la Motte L, Kehlet H, Vogt K, Nielsen CH, Groenvall JB, Nielsen HB, Andersen A, Schroeder TV, Lönn L. Preoperative methylprednisolone enhances recovery after endovascular aortic repair: a randomized, double-blind, placebo-controlled clinical trial. Ann Surg. 2014 Sep;260(3):540-8; discussion 548-9. doi: 10.1097/SLA.0000000000000895.</citation>
    <PMID>25115430</PMID>
  </reference>
  <reference>
    <citation>Dieleman JM, Nierich AP, Rosseel PM, van der Maaten JM, Hofland J, Diephuis JC, Schepp RM, Boer C, Moons KG, van Herwerden LA, Tijssen JG, Numan SC, Kalkman CJ, van Dijk D; Dexamethasone for Cardiac Surgery (DECS) Study Group. Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial. JAMA. 2012 Nov 7;308(17):1761-7. doi: 10.1001/jama.2012.14144.</citation>
    <PMID>23117776</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>April 7, 2016</last_update_submitted>
  <last_update_submitted_qc>April 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Viktoria Oline Lindberg-Larsen</investigator_full_name>
    <investigator_title>MD, research assistant</investigator_title>
  </responsible_party>
  <keyword>Glucocorticoid</keyword>
  <keyword>Complement activation</keyword>
  <keyword>Knee arthroplasty, total</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Complement System Proteins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

